tetano
Editor, Senior Moderator
Hum Vaccin Immunother
. 2022 Aug 17;2104058.
doi: 10.1080/21645515.2022.2104058. Online ahead of print.
Immunogenicity evaluation of ChAdox1 nCov-19 (AZD1222) vaccine in solid cancer patients in Chulabhorn Hospital
Piyarat Limpawittayakul[SUP] 1 [/SUP], Prakongboon Sungkasubun[SUP] 1 [/SUP], Worawit Chaiwiriyawong[SUP] 1 [/SUP], Archara Supavavej[SUP] 1 [/SUP], Bowon Weerasubpong[SUP] 1 [/SUP], Jomtana Siripaibun[SUP] 1 [/SUP], Chumut Phanthunane[SUP] 1 [/SUP], Wisut Lamlertthon[SUP] 2 [/SUP], Teerapat Ungtrakul[SUP] 2 [/SUP], Kriangkrai Tawinprai[SUP] 3 [/SUP], Walaipan Tantiyavarong[SUP] 1 [/SUP], Chayanee Samdaengpan[SUP] 1 [/SUP]
Affiliations
Abstract
Introduction: Cancer patients are more vulnerable to coronavirus disease 2019 (COVID-19) owing to their compromised immune status. However, data regarding COVID-19 vaccine safety and immune response in cancer patients are scarce.
Method: This prospective, age- and sex-matched, single-center cohort study included 61 cancer patients and 122 healthy control participants. Seropositivity was defined as anti-S IgG titer >0.8 units/ml. Primary end point was seroconversion rate of immunoglobulin (Ig)G antibodies against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein (anti-S IgG) in cancer patients vs. healthy control participants following the second dose of COVID-19 vaccine ChAdOx1 nCoV-19 (AZD1222).
Results: After the second-dose vaccination, there was no difference in seropositivity rate between groups (57 [93.44%] patients with cancer vs. 121 [99.18%] control participants; geometric mean ratio [GMR]: 0.39; 95%CI: 0.01-10.46; p-value = 0.571). In contrast, after the first-dose vaccination, the seropositivity rate was significantly lower in the cancer patients than in the control participants (50/61 [81.97%] vs. 121/122 [99.18%]; GMR: 0.07; 95%CI: 0.01-0.71; p = 0.025). The median anti-S IgG titer after the first-and second dose vaccination were not significantly different between groups. Female sex was significantly associated with a higher anti-S IgG titer. 5FU- and taxane-based chemotherapy regimens were associated with a lower IgG titer. Side effects of vaccination were tolerable.
Conclusions: The anti-S IgG seropositivity rate after completing the second vaccine dose did not differ between the cancer patients and control participants. However, the anti-S IgG seropositivity rate after the first-dose vaccination was lower in cancer patients.
Keywords: AZD1222; ChAdox1 nCov-19; seropositivity; solid cancer; titer; vaccine.
. 2022 Aug 17;2104058.
doi: 10.1080/21645515.2022.2104058. Online ahead of print.
Immunogenicity evaluation of ChAdox1 nCov-19 (AZD1222) vaccine in solid cancer patients in Chulabhorn Hospital
Piyarat Limpawittayakul[SUP] 1 [/SUP], Prakongboon Sungkasubun[SUP] 1 [/SUP], Worawit Chaiwiriyawong[SUP] 1 [/SUP], Archara Supavavej[SUP] 1 [/SUP], Bowon Weerasubpong[SUP] 1 [/SUP], Jomtana Siripaibun[SUP] 1 [/SUP], Chumut Phanthunane[SUP] 1 [/SUP], Wisut Lamlertthon[SUP] 2 [/SUP], Teerapat Ungtrakul[SUP] 2 [/SUP], Kriangkrai Tawinprai[SUP] 3 [/SUP], Walaipan Tantiyavarong[SUP] 1 [/SUP], Chayanee Samdaengpan[SUP] 1 [/SUP]
Affiliations
- PMID: 35976687
- DOI: 10.1080/21645515.2022.2104058
Abstract
Introduction: Cancer patients are more vulnerable to coronavirus disease 2019 (COVID-19) owing to their compromised immune status. However, data regarding COVID-19 vaccine safety and immune response in cancer patients are scarce.
Method: This prospective, age- and sex-matched, single-center cohort study included 61 cancer patients and 122 healthy control participants. Seropositivity was defined as anti-S IgG titer >0.8 units/ml. Primary end point was seroconversion rate of immunoglobulin (Ig)G antibodies against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein (anti-S IgG) in cancer patients vs. healthy control participants following the second dose of COVID-19 vaccine ChAdOx1 nCoV-19 (AZD1222).
Results: After the second-dose vaccination, there was no difference in seropositivity rate between groups (57 [93.44%] patients with cancer vs. 121 [99.18%] control participants; geometric mean ratio [GMR]: 0.39; 95%CI: 0.01-10.46; p-value = 0.571). In contrast, after the first-dose vaccination, the seropositivity rate was significantly lower in the cancer patients than in the control participants (50/61 [81.97%] vs. 121/122 [99.18%]; GMR: 0.07; 95%CI: 0.01-0.71; p = 0.025). The median anti-S IgG titer after the first-and second dose vaccination were not significantly different between groups. Female sex was significantly associated with a higher anti-S IgG titer. 5FU- and taxane-based chemotherapy regimens were associated with a lower IgG titer. Side effects of vaccination were tolerable.
Conclusions: The anti-S IgG seropositivity rate after completing the second vaccine dose did not differ between the cancer patients and control participants. However, the anti-S IgG seropositivity rate after the first-dose vaccination was lower in cancer patients.
Keywords: AZD1222; ChAdox1 nCov-19; seropositivity; solid cancer; titer; vaccine.